Current medical research and opinion · 2011
The use of high doses of OROS hydromorphone in an acute palliative care unit.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mercadante Sebastiano
Аннотация
OBJECTIVES: To characterize patients who received high doses of OROS hydromorphone (OROD-HY), a retrospective study of patients admitted in an acute pain relief and palliative care unit for a period of two years (from June 2009 to June 2011) was performed.
METHODS: Globally, 79 patients were prescribed OROS-HY during admission at mean maximum doses of 68 mg/day (±42). Twenty-two patients were switched from other opioids to OROS-HY and 16 patients were switched from OROS-HY to other opioids. Sixty-three patients were discharged home with a prescription of OROS-HY with doses of 53 mg/day (±44). Doses were significantly lower in older patients (p < 0.005). The mean admission time was 6.1 days (±3.2). During admission 10 patients (12.6%) were prescribed doses of OROS-HY of more than 64 mg/day.
RESULTS: The maximum mean doses of this group of patients reached during admission were 238 mg/day. Eight of them were successfully treated and discharged home with doses of 175 mg/day. Two patients did not achieve an adequate balance between analgesia and adverse effects and received alternative treatments.
CONCLUSION: This study demonstrated that OROS-HY administered in larger doses was relatively safe and effective, showing versatility and flexibility similar to other opioids.
METHODS: Globally, 79 patients were prescribed OROS-HY during admission at mean maximum doses of 68 mg/day (±42). Twenty-two patients were switched from other opioids to OROS-HY and 16 patients were switched from OROS-HY to other opioids. Sixty-three patients were discharged home with a prescription of OROS-HY with doses of 53 mg/day (±44). Doses were significantly lower in older patients (p < 0.005). The mean admission time was 6.1 days (±3.2). During admission 10 patients (12.6%) were prescribed doses of OROS-HY of more than 64 mg/day.
RESULTS: The maximum mean doses of this group of patients reached during admission were 238 mg/day. Eight of them were successfully treated and discharged home with doses of 175 mg/day. Two patients did not achieve an adequate balance between analgesia and adverse effects and received alternative treatments.
CONCLUSION: This study demonstrated that OROS-HY administered in larger doses was relatively safe and effective, showing versatility and flexibility similar to other opioids.